share_log

MCI Onehealth Enters Into Agreements With WELL Health to Sell Clinical Assets, Raise New Financing and Empower Its AI-Focused Digital Healthcare Business

MCI Onehealth Enters Into Agreements With WELL Health to Sell Clinical Assets, Raise New Financing and Empower Its AI-Focused Digital Healthcare Business

MCI Onehealth 與 WELL Health 簽訂協議,出售臨床資產,籌集新的融資,並增強其以人工智能爲重點的數字醫療保健業務
GlobeNewswire ·  2023/07/20 19:45

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

不得分發給美國新聞通訊社或在美國境內傳播

  • MCI will undergo a series of transactions that will empower its emerging AI-powered data science business, which aims to help clinicians safely and securely unlock the power of their data to improve patient outcomes.
  • MCI will sell a significant portion of its clinical assets to WELL Health Clinic Network Inc., a subsidiary of WELL Health Technologies Corp., and obtain new financing as well as a strategic alliance with WELL; positioning it to emerge as a key national platform in the multi-billion dollar rare and complex disease detection digital marketplace.
  • MCI will have a healthy balance sheet at closing, with positive working capital and a pipeline of opportunities to grow organically and inorganically in a marketplace being quickly disrupted by AI.
  • MCI將進行一系列交易,這些交易將增強其新興的人工智慧支持的數據科學業務,該業務旨在幫助臨床醫生安全可靠地釋放數據的力量,以改善患者結果。
  • MCI將把其很大一部分臨床資產出售給Well Health Technologies Corp.的子公司Well Health Clinic Network Inc.,並獲得新的融資以及與Well的戰略聯盟;使其成為價值數十億美元的罕見和複雜疾病檢測數位市場的關鍵國家平臺。
  • MCI在收盤時將擁有健康的資產負債表,擁有正的營運資本,以及在一個被人工智慧迅速顛覆的市場中實現有機和非有機增長的機會管道。

TORONTO, July 20, 2023 (GLOBE NEWSWIRE) -- MCI Onehealth Technologies Inc. ("MCI" or the "Company") (TSX: DRDR), a clinician-led healthcare technology company focused on increasing access to and quality of healthcare, announced today that it has entered into definitive agreements with WELL Health Technologies Corp. ("WELL"), that will result in MCI selling a significant portion of its clinical assets to WELL Health Clinic Network Inc., obtaining new financing and positioning MCI to emerge as a key national platform with a strong focus on AI-powered healthcare technology and clinical research (the "Transaction").

多倫多,2023年7月20日(環球網)--MCI OneHealth Technologies Inc.(以下簡稱“MCI”或“公司”)(多倫多證券交易所股票代碼:DRDR)今天宣佈,它已與Well Health Technologies Corp.(“Well”)達成最終協定,MCI將向Well Health Clinic Network Inc.出售其相當大一部分臨床資產,獲得新的融資,並將MCI定位為主要的全國性平臺,專注於人工智慧支持的醫療技術和臨床研究(“交易”)。

The Transaction is the outcome of a review of strategic alternatives which has been underway for over a year, under the supervision of a special committee of the Company consisting of two of its independent directors. Implementation of the Transaction is conditional on the receipt of all required approvals from the Toronto Stock Exchange ("TSX"), regulatory bodies and the shareholders of the Company, as well as the satisfaction of other conditions precedent.

這項交易是在本公司一個由兩名獨立董事組成的特別委員會的監督下,對戰略選擇進行了一年多的審查的結果。交易的實施取決於收到多倫多證券交易所(“多倫多證券交易所”)、監管機構和本公司股東的所有必要批准,以及是否滿足其他先決條件。

"Through this strategic transaction with WELL and its partners, MCI is taking a dramatic step forward in its plan to become a leader at the cutting-edge of data science, artificial intelligence and healthcare," said Dr. Alexander Dobranowski, CEO of the Company. "Revitalized and recapitalized, and building off the established track-record of sector innovator Khure Health's AI-driven rare and complex disease detection technology, we will be in an excellent position to become a market leader in the healthcare-AI space. Supported by our partnership and strategic alliance with WELL, we will have the tools we need to compete and innovate in the fast-paced area of healthcare-AI, both domestically and internationally, with the aim of improving care pathways and facilitating early disease detection."

通過與Well及其合作夥伴的這項戰略交易,MCI在成為數據科學、人工智慧和醫療保健前沿領導者的計劃方面向前邁出了戲劇性的一步。該公司首席執行官亞歷山大·多布拉諾夫斯基博士說。重振和資本重組,並建立在行業創新者Khure Health的人工智慧驅動的罕見和複雜疾病檢測技術的既定記錄基礎上,我們將處於極佳的地位,成為醫療保健-人工智慧領域的市場領先者。在我們與Well的合作夥伴關係和戰略聯盟的支持下,我們將擁有在國內外快節奏的醫療-人工智慧領域競爭和創新所需的工具,目的是改善護理路徑,促進疾病早期檢測。

Hamed Shahbazi, Founder and CEO of WELL commented: "We are pleased to welcome MCI's clinics, doctors and patients to the WELL family and look forward to being an engaged and helpful investor and strategic partner of MCI as it accelerates towards becoming an AI- and data-science-focused pureplay company and leader."

Well的創始人兼首席執行官哈米德·沙赫巴齊表示:“我們很高興歡迎MCI的診所、醫生和患者加入Well的大家庭,並期待成為MCI積極參與、樂於助人的投資者和戰略合作夥伴,因為它正在加速成為一家專注於人工智慧和數據科學的純遊戲公司和領導者。”

About the Transaction

關於這筆交易

Pursuant to the definitive agreements executed by the parties on July 19, 2023, the Transaction will be comprised of the following key elements:

根據雙方於2023年7月19日簽署的最終協定,該交易將包括以下關鍵要素:

Bridge Financing

過橋融資

WELL is advancing $3 million to the Company under a secured promissory note, to provide the Company with working capital to stabilize its business, continue to operate in the ordinary course and to accelerate the pursuit of its strategic plan during the interim period between signing and closing. The note bears interest at a rate of prime plus 9%, which will accrue and be payable, along with all outstanding principal, on the earlier of four months or the date the Transaction closes. The promissory note is secured against all of the present and after acquired personal property of the Company and its subsidiary, MCI Medical Clinics Inc.

Well正在以有擔保的本票向本公司預付300萬美元,為本公司提供營運資金,以穩定其業務,繼續正常運營,並在簽署至完成交易之間的過渡期間加速實現其戰略計劃。票據的利息為最優惠利率加9%,利息將與所有未償還本金一起於四個月前或交易完成之日應計並支付。本票以公司及其子公司MCI醫療診所公司目前和收購後的所有個人財產為抵押。

Convertible Debenture Financing

可轉換債券融資

The Company will complete a convertible debenture financing to raise between $7.5 million and $10 million, to fund working capital and support future M&A activity while it focuses on growing its data-driven, AI-enabled healthcare technology offerings. WELL will participate in the financing as lead investor, for a minimum of $2.5 million of the total financing.

該公司將完成可轉換債券融資,籌集750萬至1000萬美元,為營運資本提供資金,並支持未來的並購活動,同時專注於增長其數據驅動型、人工智慧支持的醫療技術產品。Well將作為牽頭投資者參與融資,至少佔總融資的250萬美元。

The debentures will be unsecured obligations of the Company, mature 5 years from the date the financing closes, and bear interest at a rate of 10% per annum, which will be payable at maturity. The principal and interest outstanding under the debentures will be convertible into Class A Subordinate Voting Shares of the Company ("Class A Shares") at any time, at the option of the holder, at a conversion price of $0.20/share. Participants in the convertible debenture financing will also receive, for every $1 of debentures, 5 warrants for Class A Shares exercisable at a price of $0.20/share.

該等債權證將為本公司的無抵押債務,自融資結束之日起計滿5年,年利率為10%,於到期時支付。債券項下已發行的本金及利息可隨時根據持有人的選擇轉換為本公司的A類附屬投票權股份(“A類股份”),換股價格為每股0.2美元。可轉換債券融資的參與者還將獲得每1美元債券中5股A類股票的認股權證,可按每股0.20美元的價格行使。

The financing is conditional on, among other things, the Company obtaining approval from the TSX and its shareholders for the proposed conversion and exercise price of the debentures and warrants, as well as the size of the raise and corresponding dilution.

融資的條件包括(其中包括)本公司獲得多倫多證券交易所及其股東對債券及認股權證的建議轉換及行使價的批准,以及集資及相應攤薄的規模。

Sale of Ontario Clinics

出售安大略省診所

The Company will sell to WELL, under an asset purchase agreement between their respective subsidiaries, eleven of its fourteen medical clinics in Ontario, along with other related assets, for a purchase price of $1.5 million.

根據各自子公司之間的資產購買協定,該公司將把其在安大略省的14家醫療診所中的11家連同其他相關資產出售給Well,收購價格為150萬美元。

The acquired clinics will join WELL's extensive and efficiently run network of clinics, the largest owned and operated network in Canada, ensuring stability and continued quality of care for patients and healthcare professionals. The Company's flagship Polyclinic group of clinics will be retained by the Company, and will continue to contribute to the Company's technology-enabled healthcare research offerings.

被收購的診所將加入Well的廣泛和高效運營的診所網路,這是加拿大最大的擁有和運營的網路,確保為患者和醫療保健專業人員提供穩定和持續的護理質量。公司的旗艦綜合診所集團將由公司保留,並將繼續為公司的技術支持的醫療研究產品做出貢獻。

The sale of the Ontario clinics is subject to standard closing conditions typical for transactions of a similar nature and kind, and is expected to close concurrently with the convertible debenture financing noted above.

安大略省診所的出售須遵守類似性質和種類交易的標準成交條件,預計將與上述可轉換債券融資同時完成。

Secured Debt Resolution

有擔保債務解決方案

In connection with the Transaction, it is anticipated that the Company will fully satisfy and discharge its outstanding secured credit facility with TD Bank. The Transaction also contemplates a solution for the Company's existing secured credit facilities with The First Canadian Wellness Co. Inc. (the "Lender"), a related party to the Company, under which the Company presently owes an aggregate of approximately $9.0 million in principal and accrued fees and interest. Under the definitive agreements for the Transaction:

就該交易而言,預期本公司將完全清償及清償其與道明銀行的未償還抵押信貸安排。這項交易還考慮解決公司與第一加拿大健康公司(“貸款人”)之間現有的擔保信貸安排。第一加拿大健康公司是公司的關聯方,根據該公司目前欠下的本金和應計費用和利息總額約為900萬美元。根據交易的最終協定:

  • The Company will deliver, as soon as reasonably practicable and subject to TSX, shareholder and third-party approvals, certain non-core assets to the Lender in full satisfaction of the $1.5 million facility that was made available to the Company by the Lender on May 18, 2023 (the "New Facility").
  • The Company will pay $600,000 to the Lender to partially satisfy the balance of the Company's outstanding obligations to Lender.
  • WELL will purchase the remainder of the secured credit facility from the Lender and, at closing of the Transaction, will settle, compromise, release or otherwise discharge the obligations of the Company and certain of its subsidiaries under that facility.
  • 本公司將在合理可行範圍內儘快向貸款人交付若干非核心資產,以完全清償貸款人於2023年5月18日向本公司提供的150萬美元貸款(“新貸款”),但須獲得多倫多證券交易所、股東及第三方的批准。
  • 公司將向貸款人支付60萬美元,以部分償還公司對貸款人的未償債務餘額。
  • Well將向貸款人購買擔保信貸安排的剩餘部分,並在交易完成時結算、妥協、解除或以其他方式履行本公司及其若干附屬公司在該安排下的義務。

As a result of the foregoing, it is anticipated that the obligations of the Company and certain of its subsidiaries under the secured credit facility from the Lender will be satisfied and discharged through the Transaction, with the balance of the Company's subsidiaries to be discharged post-closing following the satisfaction of certain conditions. This element of the Transaction is not conditional on the completion of other aspects of the Transaction.

由於上文所述,預期本公司及其若干附屬公司在貸款人的擔保信貸安排下的責任將透過交易獲得履行及解除,而本公司附屬公司的餘額將於若干條件滿足後於完成交易後清償。交易的這一要素不以交易的其他方面的完成為條件。

Dr. George Christodoulou and Dr. Sven Grail, directors, co-Chairs and control persons of the Company, control the Lender, and Mr. Kingsley Ward and Mr. Anthony Lacavera, directors of the Company, each have a 1/6th financial interest in the New Facility. As such, the transfer of the Non-Core Assets to the Lender constitutes a related party transaction under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101").

公司董事、聯席主席和控制人George Christodoulou博士和Sven Grail博士控制貸款人,公司董事金斯利·沃德先生和安東尼·拉卡維拉先生分別擁有1/6的股份這是在新設施中的財務權益。因此,根據多邊文書61-101,將非核心資產轉讓給貸款人構成關聯方交易-特殊交易中少數股權持有人的保護(“MI 61-101”)。

The transfer of the non-core assets to the Lender in satisfaction of the New Facility has been unanimously approved by those directors of the Company who do not have an interest in the transaction, with interested directors abstaining from voting and deliberations on the approval. The Company is exempt from the formal valuation requirement under MI 61-101 as the fair market value of the non-core assets does not exceed more than 25% of the market capitalization of the Company on the date the transfer was agreed to. The Company is also exempt from the minority approval requirement under MI 61-101 on the foregoing basis. The Company did not file a material change report 21 days in advance of implementing the transfer as arrangements for the transfer of the non-core assets to the Lender in satisfaction of the New Facility were only recently settled.

向貸款人轉讓非核心資產以清償新貸款,已獲在交易中並無利害關係的本公司董事一致批准,而有利害關係的董事則放棄投票及審議批准事項。由於非核心資產的公平市值不超過同意轉讓當日本公司市值的25%,本公司獲豁免遵守MI 61-101規定的正式估值要求。在上述基礎上,本公司亦獲豁免遵守MI 61-101規定的少數股東批准要求。本公司並無於實施轉讓前21天提交重大變動報告,因為向貸款人轉讓非核心資產以清償新貸款的安排最近才敲定。

Call Option

呼叫選項

WELL will be granted a call option from certain shareholders of the Company, which gives WELL the right to acquire up to 30.8 million Class A Shares and 30.8 million Class B Multiple Voting Shares of the Company ("Class B Shares") representing an aggregate of approximately 81.5% of the votes attributable to all issued and outstanding shares of the Company.

Well將獲本公司若干股東授予認購期權,賦予Well權利收購本公司最多3,080,000股A類股份及3,080,000股B類多重投票權股份(“B類股份”),相當於本公司所有已發行及已發行股份合共約81.5%的投票權。

The exercise of the option is conditional on the achievement by the Company of a number of performance milestones designed to demonstrate improvements in the Company's financial and capital markets performance, as well as obtaining any required TSX or regulatory approvals. The option can only be exercised in pairs, such that WELL must concurrently acquire a Class A Share and a Class B Share, and is exercisable for 36 months post-closing. The exercise of the call option is expected to proceed under the private agreement exemption in National Instrument 62-104 – Take-over Bids and Issuer Bids (NI 62-104), such that the price of the call option would not be permitted to exceed 115% of the market price of the Class A Shares at the time of exercise. If at the time of exercise, the exercise price would exceed 115% of the market price of the Class A Shares, the exercise would be subject to the standard rules and procedures applicable to take-over bids under NI 62-104.

行使購股權的條件是本公司達到若干業績里程碑,旨在證明本公司的財務和資本市場業績有所改善,以及獲得任何所需的多倫多證券交易所或監管機構的批准。購股權只能成對行使,即Well必須同時收購A類股和B類股,並在交易完成後36個月內可行使。根據《國家文書62-104》中的私人協定豁免,預計將繼續行使看漲期權-接管投標和發行人投標(NI 62-104),因此認購期權的價格不得超過行使時A類股份市價的115%。如果在行使時,行使價格將超過A類股票市價的115%,行使將受適用於根據NI 62-104進行的收購要約的標準規則和程式所規限。

This aspect of the Transaction requires an amendment to the Company's articles to add WELL as an authorized holder of the Class B Multiple Voting Shares, which will be subject to obtaining disinterested shareholder approval at a shareholder meeting of the Company.

交易的這一方面需要對公司章程進行修訂,以增加B類多重投票權股份的授權持有人,這將需要在公司的股東大會上獲得無利害關係的股東批准。

Other Key Terms

其他關鍵術語

Other material aspects of the Transaction will include:

這筆交易的其他重要方面包括:

  • Entering into an investor rights agreement providing WELL with, among other things (a) the right to nominate up to (i) 2 directors or non-voting board observers of the Company, or (ii) a majority of the directors or non-voting board observers of the Company in the event that WELL becomes a control person of the Company having more than 20% of the voting rights attached to all outstanding voting securities of the Company; (b) pre-emptive rights in respect of future issuances of securities of the Company, and (c) qualification and registration rights, in each case subject to standard terms and conditions.
  • WELL and the Company will enter into a strategic alliance agreement at closing of the Transaction, which will provide the Company with an enhanced platform from which to execute on its data-driven, AI-enabled healthcare technology offerings.
  • The holders of the 6 million Class B Shares not subject to the call option have agreed to surrender their Class B Shares to the Company for cancellation without consideration upon closing of the Transaction.
  • 訂立投資者權利協定,賦予(其中包括)(A)提名最多(I)2名本公司董事或無投票權董事會觀察員的權利,或(Ii)在本公司所有已發行有投票權證券附帶超過20%投票權的情況下成為本公司控制人時提名最多2名本公司董事或無投票權董事會觀察員的權利;(B)有關本公司未來發行證券的優先購買權;及(C)資格及登記權,每項權利均受標準條款及條件規限。
  • Well和公司將在交易完成時達成戰略聯盟協定,這將為公司提供一個增強的平臺,以執行其數據驅動的、支援人工智慧的醫療技術產品。
  • 不受認購期權約束的600萬股B類股的持有人已同意在交易完成時將其B類股交還給本公司註銷,而不對其進行對價。

Additional Information on the Transaction

有關交易的其他資訊

Copies of the definitive agreements for the Transaction will be made available for review on the Company's SEDAR page at and the Company will disclose any additional material information about the Transaction in due course.

交易的最終協定副本將在公司的SEDAR頁面上提供,以供查閱,公司將在適當時候披露有關交易的任何其他重要資訊。

Completion of the Transaction is subject to a number of conditions precedent, including but not limited to (a) TSX approvals, (b) shareholder approvals, and (c) other conditions precedent typical for transactions of this nature and kind. If the conditions precedent cannot be satisfied or (if applicable) waived, the Transaction (or individual components of the Transaction) will not close. Moreover, there can be no assurance at this time that the Transaction, or any individual component of the Transaction, will be completed as proposed or at all.

交易的完成取決於一些先決條件,包括但不限於(A)多倫多證券交易所的批准,(B)股東的批准,以及(C)此類交易的典型先決條件。如果先行條件不能滿足或(如果適用)放棄,交易(或交易的個別組成部分)將不會結束。此外,目前還不能保證交易或交易的任何個別組成部分將按建議完成或根本不能完成。

Investors are cautioned that, except as disclosed in the management information circular to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the Company's securities in anticipation of the completion of the Transaction, or any individual component of the Transaction, should be considered highly speculative.

投資者請注意,除非在與交易相關的管理資料通函中披露,否則所發佈或收到的有關交易的任何資訊可能不準確或不完整,不應依賴。在預期交易完成或交易的任何個別組成部分的情況下交易公司證券,應被視為高度投機性。

The TSX has not considered or made any determination on the merits of the proposed Transaction and have neither approved nor disapproved of this press release.

多倫多證券交易所沒有考慮或對擬議交易的優點做出任何決定,也沒有批准或反對本新聞稿。

Annual General and Special Meeting of Shareholders

股東周年大會及特別大會

The Company expects to call an annual general and special meeting of its shareholders to consider and approve the Transaction in the near-term. Additional details concerning the meeting, and accompanying management information circular, will be disseminated in due course.

該公司預計將在短期內召開年度股東大會和特別會議,審議和批准這筆交易。有關會議的更多詳情,以及隨附的管理資料通告,將於適當時候分發。

About MCI
MCI is a healthcare technology company focused on empowering patients and doctors with advanced technologies and data-driven clinical insights to increase access, improve quality, and reduce healthcare costs. Led by a proven management team of doctors and experienced executives, MCI remains focused on executing a strategy centered around acquiring technology and health services that complement the company's current roadmap. For more information, visit mcionehealth.com.

關於MCI
MCI是一家醫療技術公司,專注於用先進的技術和數據驅動的臨床洞察來增強患者和醫生的能力,以增加訪問、提高質量和降低醫療成本。在一支由醫生和經驗豐富的高管組成的成熟管理團隊的領導下,MCI仍然專注於執行一項以獲取技術和健康服務為中心的戰略,以補充公司目前的路線圖。如需更多資訊,請訪問Mcionehealth.com

About WELL

關於井

WELL's mission is to tech-enable healthcare providers. WELL does this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 28,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 130 clinics supporting primary care, specialized care and diagnostic services. In the United States WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol "WELL" and on the OTC Exchange under the symbol "WHTCF". To learn more about the Company, please visit:

Well的使命是為醫療保健提供者提供技術支持。通過開發最好的技術、服務和支持來很好地做到這一點,這確保了醫療保健提供者有能力積極影響患者的結果。Well全面的醫療保健和數字平臺包括廣泛的前臺和後臺管理軟體應用程式,幫助醫生運行和保護他們的業務。Well的解決方案為美國和加拿大之間的28,000多家醫療保健提供商提供服務,並為加拿大擁有和運營的最大的醫療保健生態系統提供動力,該生態系統擁有130多家診所,為初級保健、專門護理和診斷服務提供支持。在美國,Well的解決方案專注於胃腸道市場、婦女健康、初級保健和精神健康等專門市場。Well在多倫多證券交易所公開交易,代碼為“Well”,在場外交易市場的交易代碼為“WHTCF”。要了解更多有關該公司的資訊,請訪問:

For media enquiries please contact:
Nolan Reeds | nolan@mcionehealth.com

傳媒查詢,請聯絡:
諾蘭·裡茲|Nolan@mcioneHealth.com

Forward Looking Statements

前瞻性陳述

Certain statements in this press release, constitute "forward-looking information" and "forward looking statements" (collectively, "forward looking statements") within the meaning of applicable Canadian securities laws and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements include statements with respect to the anticipated completion of the strategic transaction and its various elements, the terms on which the strategic transaction will be completed, the go-forward business of the Company following completion of the strategic transaction, and the calling of a shareholder meeting for the Company. The words "obtain", "implement", "taking", "to become", "aim", "improve", "facilitating", "accelerating", "growing", "ensuring", "continue", "contribute", "anticipate", "expects", "contemplates", "complete", "engaged", "potential", "future", "remains", "consider", "result in", "increase", "deliver", "emerge", "is conditional", "plan", "look forward to", "subject to" or variations of such words and phrases or statements that certain future conditions, actions, events or results "will", "may", "could", "would", "should", "might" or "can", or negative versions thereof, "occur", "continue" or "be achieved", and other similar expressions, identify forward-looking statements. Forward-looking statements are necessarily based upon management's perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by MCI as of the date of such statements, are outside of MCI's control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: MCI's ability to satisfy any conditions precedent and complete the Transaction; MCI's ability to obtain the necessary TSX, regulatory and shareholder approvals required for the completion of the Transaction; MCI's ability to complete the Transaction or to complete it on the terms described above; MCI's ability to maintain its relationships and to successfully integrate its business with WELL; MCI's ability to hold its annual general and special meeting of shareholders within the prescribed time periods; MCI's ability to satisfy and discharge its outstanding debt facilities and other indebtedness; MCI's plans for future cost reduction; the availability of working capital and sources of liquidity; MCI's ability to continue to operate as a going concern; the anticipated terms of the strategic alliance agreement with WELL; MCI's ability to achieve its growth and revenue strategies; the demand for MCI's products and fluctuations in future revenues; the availability of future business ventures, commercial arrangements and acquisition targets or opportunities and MCI's ability to consummate them and to effectively integrate future acquisition targets into its platform; the effects of competition in the industry; the requirement for increasingly innovative product solutions and service offerings; trends in customer growth; the stability of general economic and market conditions; currency exchange rates and interest rates; MCI's ability to comply with applicable laws and regulations; MCI's continued compliance with third party intellectual property rights; and that the risk factors noted below, collectively, do not have a material impact on MCI's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved.

本新聞稿中的某些陳述構成適用於加拿大證券法的“前瞻性資訊”和“前瞻性陳述”(統稱為“前瞻性陳述”),基於截至本新聞稿發佈之日的假設、預期、估計和預測。前瞻性陳述包括有關預期完成戰略交易及其各種要素、完成戰略交易的條款、完成戰略交易後公司的未來業務以及召開公司股東大會等方面的陳述。“獲得”、“實施”、“取得”、“成為”、“目標”、“改進”、“便利”、“加速”、“成長”、“確保”、“繼續”、“貢獻”、“預期”、“預期”、“設想”、“完成”、“參與”、“潛力”、“未來”、“保留”、“考慮”、“結果”、“增加”、“交付”、“湧現”,“是否有條件”、“計劃”、“期待”、“受制於”或此類詞語和短語的變體或某些未來條件、行動、事件或結果“將”、“可能”、“可能”、“應該”、“可能”或“可以”或其否定表達形式、“發生”、“繼續”或“將實現”以及其他類似表述,均為前瞻性表述。前瞻性陳述必須基於管理層對歷史趨勢、當前狀況和預期未來發展的看法,以及一些特定因素和假設,儘管MCI認為這些因素和假設在這些陳述發表之日是合理的,但這些因素和假設不在MCI的控制範圍之內,本身就會受到重大的商業、經濟和競爭不確定性和意外事件的影響,這些不確定性和意外事件可能導致前瞻性陳述最終完全或部分不正確或不真實。本新聞稿中包含的前瞻性陳述基於各種假設,包括但不限於:MCI滿足任何先決條件並完成交易的能力;MCI獲得完成交易所需的多倫多證券交易所、監管機構和股東批准的能力;MCI完成交易或按上述條款完成交易的能力;MCI維持其關係並成功地將其業務與Well整合的能力;MCI在規定期限內召開年度股東大會和特別大會的能力;MCI償還和清償未償債務安排和其他債務的能力;MCI未來降低成本的計劃;營運資金的可用性和流動性來源;MCI繼續作為持續經營的企業的能力;與Well的戰略聯盟協定的預期條款;MCI實現其增長和收入戰略的能力;對MCI產品的需求和未來收入的波動;未來商業投資、商業安排和收購目標或機會的可用性,以及MCI完成它們並將未來收購目標有效地整合到其平臺中的能力;行業競爭的影響;對日益創新的產品解決方案和服務的要求;客戶增長的趨勢;總體經濟和市場條件的穩定性;貨幣匯率和利率;MCI遵守適用法律和法規的能力;MCI繼續遵守第三方知識產權的能力;以及下述風險因素共同對MCI的業務、運營、收入和/或業績沒有實質性影響。就其性質而言,前瞻性陳述存在固有的風險和不確定性,這些風險和不確定性可能是一般性的,也可能是具體的,導致預期、預測或結論被證明不準確,假設可能不正確,目標、戰略目標和優先事項無法實現。

Known and unknown risk factors, many of which are beyond the control of MCI, could cause the actual results of MCI to differ materially from the results, performance, achievements or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled "Risk Factors" in MCI's annual information form dated March 31, 2023, which is available under MCI's SEDAR profile at . The risk factors are not intended to represent a complete list of the factors that could affect MCI and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. MCI disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.

已知和未知的風險因素,其中許多都不在MCI的控制範圍之內,可能導致MCI的實際結果與此類前瞻性陳述明示或暗示的結果、業績、成就或發展大相徑庭。此類風險因素包括但不限於在MCI日期為2023年3月31日的年度資訊表中“風險因素”一節中討論的那些因素,該表可在MCI的SEDAR簡介下查閱。風險因素並不代表可能影響MCI的因素的完整清單,提醒讀者仔細考慮這些和其他因素、不確定性和潛在事件,不要過度依賴前瞻性陳述。不能保證前瞻性陳述將被證明是準確的,因為實際結果和未來事件可能與此類陳述中預期的大不相同。提供前瞻性陳述是為了提供有關管理層對未來的期望和計劃的資訊。除非適用法律要求,否則MCI沒有任何意圖或義務更新或修改任何前瞻性陳述,無論是由於新資訊、未來事件或其他原因,也不解釋後續實際事件與此類前瞻性陳述之間的任何實質性差異。本新聞稿中包含的所有前瞻性陳述均受這些警告性聲明的限制。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論